Abstract
Laryngeal cancer is a common head and neck cancer. Despite advances in treatment, improvement in survival and quality of life of patients still remains a challenge. Chemotherapy has become more and more important since this treatment is able to preserve laryngeal function. There is increasing evidence showing that many chemotherapeutic agents kill laryngeal tumor cells via apoptotic mechanisms. The balance between anti-apoptotic molecules and pro-apoptotic ones plays a critical role in determining the sensitivity of the tumor cells to chemotherapy. The commonly used chemotherapeutic agents for laryngeal cancer include cisplatin, 5-fluorouracil and paclitaxel. These three agents may target common apoptotic molecules, but more importantly they have their own particular targets. Systemically analysis of these targets will not only help to optimize the treatment but also provide a rationale for the best combination of two or more agents for the chemotherapy of laryngeal cancer.
Keywords: Laryngeal cancer, apoptosis, cisplatin, 5-fluorouracil, paclitaxel
Current Drug Targets
Title: Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Volume: 9 Issue: 10
Author(s): Han Ching Liu, George G. Chen, Alexander C. Vlantis, Michael C.F. Tong and C. Andrew van Hasselt
Affiliation:
Keywords: Laryngeal cancer, apoptosis, cisplatin, 5-fluorouracil, paclitaxel
Abstract: Laryngeal cancer is a common head and neck cancer. Despite advances in treatment, improvement in survival and quality of life of patients still remains a challenge. Chemotherapy has become more and more important since this treatment is able to preserve laryngeal function. There is increasing evidence showing that many chemotherapeutic agents kill laryngeal tumor cells via apoptotic mechanisms. The balance between anti-apoptotic molecules and pro-apoptotic ones plays a critical role in determining the sensitivity of the tumor cells to chemotherapy. The commonly used chemotherapeutic agents for laryngeal cancer include cisplatin, 5-fluorouracil and paclitaxel. These three agents may target common apoptotic molecules, but more importantly they have their own particular targets. Systemically analysis of these targets will not only help to optimize the treatment but also provide a rationale for the best combination of two or more agents for the chemotherapy of laryngeal cancer.
Export Options
About this article
Cite this article as:
Liu Ching Han, Chen G. George, Vlantis C. Alexander, Tong C.F. Michael and van Hasselt Andrew C., Chemotherapy for Laryngeal Cancer - An Apoptotic Approach, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909257
DOI https://dx.doi.org/10.2174/138945008785909257 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Malignant Hypercalcemia
Current Medicinal Chemistry Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Organ-Level Tissue Engineering Using Bioreactor Systems and Stem Cells: Implications for Transplant Surgery
Current Stem Cell Research & Therapy A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Chitosan Surface-Modified PLGA Nanoparticles: Preparation, Characterization, and Evaluation of their In Vitro Drug-Release Behaviors and Cytotoxicities
Current Nanoscience Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Non-Invasive Biomarkers of Lung Inflammation in Smoking Subjects
Current Medicinal Chemistry Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Imaging Virus-Associated Cancer
Current Pharmaceutical Design Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry